Author:
Bagheri-Hosseinabadi Zahra,Moadab Fatemeh,Amiri Ali,Abbasifard Mitra
Abstract
Abstract
Background
Components of metabolic syndrome (MetS) was reported to contribute to severe and worse outcomes of coronavirus disease 2019 (COVID-19). Hereby, we evaluated the association of MetS and its components with susceptibility to COVID-19.
Methods
Here, 1000 subjects with MetS were recruited that were diagnosed via the International Diabetes Federation (IDF) criterion. Real-time PCR was exerted to detect SARS-CoV-2 in the nasopharyngeal swabs.
Results
Among the MetS patients, 206 (20.6%) cases were detected to have COVID-19. Smoking (OR = 5.04, 95%CI = 3.53–7.21, P < 0.0001) and CVD (OR = 1.62, 95%CI = 1.09–2.40, P = 0.015) were associated with increased chance of COVID-19 infection in the MetS patients. BMI was significantly higher (P = 0.0001) in MetS cases with COVID-19 than those without COVID-19. Obesity was associated with increased susceptibility to COVID-19 in MetS patients (OR = 2.00, 95%CI = 1.47–2.74, P < 0.0001). Total cholesterol, TG, LDL were significantly higher in the MetS cases with COVID-19 than those without COVID-19. Dyslipidemia was associated with increased chance of COVID-19 (OR = 1.50, 95%CI = 1.10–2.05, P = 0.0104). FBS level was significantly higher in the MetS cases with COVID-19. T2DM was associated with increased risk of COVID-19 in MetS patients (OR = 1.43, 95%CI = 1.01-2.00, P = 0.0384). Hypertension was associated with increased chance of COVID-19 in the MetS patients (OR = 1.44, 95%CI = 1.05–1.98, P = 0.0234).
Conclusions
MetS and its components, like obesity, diabetes, dyslipidemia, cardiovascular complications were associated with increased chance of COVID-19 infection development and probably with aggravated symptoms in such patients.
Funder
Rafsanjan University of Medical Sciences
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Endocrinology, Diabetes and Metabolism
Reference38 articles.
1. Abobaker A, Raba AA, Alzwi A. Extrapulmonary and atypical clinical presentations of COVID-19. Journal of medical virology. 2020;92(11):2458–64.
2. Mohammadhosayni M, Mohammadi FS, Ezzatifar F, Gorabi AM, Khosrojerdi A, Aslani S, et al. Matrix metalloproteinases are involved in the development of neurological complications in patients with coronavirus disease 2019. International immunopharmacology. 2021;100:108076.
3. Ramezani S, Ezzatifar F, Hojjatipour T, Hemmatzadeh M, Shabgah AG, Navashenaq JG, et al. Association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients. Molecular Biology Reports. 2023;50(1):173–83.
4. Ebrahimi N, Aslani S, Babaie F, Hemmatzadeh M, Hosseinzadeh R, Joneidi Z, et al. Recent findings on the coronavirus disease 2019 (COVID-19)
5. immunopathogenesis and immunotherapeutics. International immunopharmacology. 2020:107082.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献